Literature DB >> 1937795

Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers.

G Arakere1, C E Frasch.   

Abstract

Most group C Neisseria meningitidis strains produce an O-acetyl-positive polysaccharide, a homopolymer of alpha-2----9-linked N-acetylneuraminic acid with O-acetyl groups at the C-7 and C-8 of its sialic acid residues. The majority of disease isolates have been reported to contain this polysaccharide. Some strains produce group C polysaccharide lacking O-acetyl groups. The licensed vaccine contains the O-acetyl-positive polysaccharide. We have measured the antibody specificities to the two polysaccharides in sera from asymptomatic group C meningococcal carriers and vaccinated adults by a new enzyme-linked immunosorbent assay (ELISA) procedure using methylated human serum albumin for coating the group C polysaccharide onto microtiter plates. Inhibition of binding of serum antibodies to polysaccharide-coated plates was measured by ELISA after incubation with O-acetyl-positive and O-acetyl-negative group C polysaccharides. Greater inhibition of binding of carrier sera was observed with the homologous polysaccharide. There was substantial inhibition of binding of vaccinee sera to the O-acetyl-positive polysaccharide-coated plate following preincubation with O-acetyl-positive polysaccharide, but homologous inhibition on plates coated with the O-acetyl-negative polysaccharide required much higher concentrations of polysaccharide. Carrier sera may have a higher proportion of antibodies with greater specificity for the O-acetyl-negative polysaccharide, while vaccinee sera contain antibodies with greater affinity for the O-acetyl-positive polysaccharide. Studies with monoclonal antibodies specific for O-acetyl-positive and O-acetyl-negative polysaccharides reveal that the percentage of group C meningococcal disease caused by O-acetyl-negative strains remains about 15%, as found over 15 years ago.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1937795      PMCID: PMC259048          DOI: 10.1128/iai.59.12.4349-4356.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  A fractionating column for analysis of nucleic acids.

Authors:  J D MANDELL; A D HERSHEY
Journal:  Anal Biochem       Date:  1960-06       Impact factor: 3.365

Review 2.  RNA fractionation on Kieselguhr columns.

Authors:  R M Kothari; V Shankar; M W Taylor
Journal:  J Chromatogr       Date:  1972-08-23

3.  Elution of human satellite DNAs on a methylated albumin kieselguhr chromatographic column: isolation of satellite DNA. IV.

Authors:  G Corneo; L Zardi; E Polli
Journal:  Biochim Biophys Acta       Date:  1972-05-10

4.  Identification of a subgroup antigen on the Neisseria meningitidis group C capsular polysaccharide.

Authors:  M A Apicella
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

5.  Bactericidal antibody after colonization with Neisseria meningitidis.

Authors:  L B Reller; R R MacGregor; H N Beaty
Journal:  J Infect Dis       Date:  1973-01       Impact factor: 5.226

Review 6.  Development of polysaccharide vaccines for the prevention of meningococcal diseases.

Authors:  E C Gotschlich
Journal:  Monogr Allergy       Date:  1975

7.  Meningococcal group C subgroup determinant detected by immunofluorescence.

Authors:  M A Apicella; H A Feldman
Journal:  Proc Soc Exp Biol Med       Date:  1976-07

8.  Role of protein serotype antigens in protection against disease due to Neisseria meningitidis.

Authors:  C E Frasch
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

9.  Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.

Authors:  C E Frasch; J D Robbins
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  27 in total

1.  Analysis of human serum immunoglobulin G against O-acetyl-positive and O-acetyl-negative serogroup W135 meningococcal capsular polysaccharide.

Authors:  Peter C Giardina; Emma Longworth; Renee E Evans-Johnson; Michaelene L Bessette; Hong Zhang; Ray Borrow; Dace Madore; Philip Fernsten
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

2.  Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.

Authors:  S J Devi; W D Zollinger; P J Snoy; J Y Tai; P Costantini; F Norelli; R Rappuoli; C E Frasch
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

3.  Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.

Authors:  Maija Toropainen; Leena Saarinen; Elisabeth Wedege; Karin Bolstad; Terje E Michaelsen; Audun Aase; Helena Käyhty
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Measurement of antibodies against meningococcal capsular polysaccharides B and C in enzyme-linked immunosorbent assays: towards an improved surveillance of meningococcal disease.

Authors:  J Andersen; L Berthelsen; I Lind
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

5.  Activity and cross-reactivity of antibodies induced in mice by immunization with a group B meningococcal conjugate.

Authors:  D Coquillat; J Bruge; B Danve; M Latour; C Hurpin; D Schulz; P Durbec; G Rougon
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  Determination of parallelism and nonparallelism in bioassay dilution curves.

Authors:  B D Plikaytis; P F Holder; L B Pais; S E Maslanka; L L Gheesling; G M Carlone
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

7.  Involvement of phospholipid end groups of group C Neisseria meningitidis and Haemophilus influenzae type b polysaccharides in association with isolated outer membranes and in immunoassays.

Authors:  G Arakere; A L Lee; C E Frasch
Journal:  J Bacteriol       Date:  1994-02       Impact factor: 3.490

8.  Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992.

Authors:  P K Holder; S E Maslanka; L B Pais; J Dykes; B D Plikaytis; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

9.  Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine.

Authors:  A E Platonov; V B Beloborodov; L I Pavlova; I V Vershinina; H Käyhty
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

10.  Discovery and characterization of sialic acid O-acetylation in group B Streptococcus.

Authors:  Amanda L Lewis; Victor Nizet; Ajit Varki
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.